| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2001; 40: 111-112
© 2001 British Society for Rheumatology
Letters to the Editor |
Antiphospholipid antibody system in systemic sclerosis
DiSEM Section of Dermatology, University of Genoa, Viale Benedetto XV no. 7, 16132 Genoa and
1 Bouty s.p.a., Milan, Italy
| The first 10% of the full text of this article appears below. |
SIR, Anti-phospholipid antibodies (aPLa) are a heterogeneous family of immunoglobulins directed to negatively charged phospholipids binding particular plasma proteins that behave as co-factors, e.g. ß 2 glycoprotein I (ß 2-GPI), prothrombin, protein C, protein S and annexin V. aPLa characterize the anti-phospholipid syndrome with thrombosis, thrombocytopenia and recurrent spontaneous abortions, but they can also be detected in connective tissue diseases, in particular systemic lupus erythematosus, and, more rarely, in lymphoproliferative disorders and infectious diseases